2018 American Transplant Congress
Heart Transplant across Low or Moderate Level Donor-Specific Antibodies Have Acceptable Outcome
Cedars Sinai Medical Center, Los Angeles.
Purpose: The presence of pre-transplant donor specific antibodies (DSA) can reduce the likelihood of a patient (pt) obtaining a compatible donor heart. The proportion of…2018 American Transplant Congress
Influence of Trough Level in Tacrolimus on the Appearance Rate of De Novo Donor Specific Antibody (dnDSA) under Low Dose-Based Tacrolimus Protocol during 7 Years Follow-Up after Renal Transplantation
Background. Tacrolimus low trough protocol has been adopted at our institution since 2000.The purpose in this study is to investigate the relationship between maintenance trough…2018 American Transplant Congress
Shared HLA Specificities between the Blood and Transplant Donor Increases the Risk of De Novo DSA Development Following Blood Transfusion in Transplant Recipients
Introduction: Blood transfusions post-transplant have been shown to be associated with the development of de novo DSA and inferior allograft outcomes. The mechanisms behind this…2018 American Transplant Congress
Clinical Significance of Microvascular Inflammation in the Absence of Anti-HLA DSA in Kidney Transplantation
University of Wisconsin, Madison.
Background: It is not uncommon to have biopsy specimens meeting Banff glomerulitis (g) plus peritubular capillaritis (ptc) and/or c4d scores that meet criteria for antibody…2018 American Transplant Congress
What Threshold MFI is the Luminex 1:8 Dilution the Poor Man's C1q for Patients Awaiting Heart Transplant?
Cedars Sinai Medical Center, Los Angeles.
Purpose: Heart transplant candidates are evaluated for anti-HLA antibodies by Luminex single-antigen bead testing to avoid donors that may harbor antigens that these antibodies are…2018 American Transplant Congress
The Impact of Lymphocele Formation after Kidney Transplantation on De Novo Donor Specific Antibody Formation
Introduction: Lymphocele formation is a common complication after kidney transplantation and has been linked to rejection episodes. However, long-term outcome data are scarce and the…2018 American Transplant Congress
Role of C1q-Binding Donor-Specific Anti-HLA Antibodies in Premature and Accelerated Kidney Allograft Interstitial Fibrosis
Paris Translational Research Center for Organ Transplantation, Paris, France.
The 2017 Banff meeting has focused on the importance of a precise diagnosis of IF/TA in kidney recipients by addressing specific etiological factors. Recent studies…2018 American Transplant Congress
Waning Enthusiasm for a Once Promising Test: C1q Testing Does Not Provide Prognostic Information for DSA Screening Protocols
Medstar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC.
Introduction: Testing of donor specific antibodies (DSA) for binding of complement component C1q has been used to better elucidate pathologic antibodies from more benign reactions.…2018 American Transplant Congress
Pre-Transplant Memory Patients Even without Detected Antibody Are at Rejection Risk in the First-Year after Heart Transplantation
Cedars Sinai Medical Center, Los Angeles.
Purpose: Patients (pts) with prior transplants, blood transfusions, and pregnancies awaiting heart transplantation (HTx) have potential to develop circulating anti-HLA antibodies (HLA Abs). Pts at…2018 American Transplant Congress
Single Center Experience of HLA-Related Donor Specific Antibody in Living Donor Liver Transplantation
Although impact of donor specific antibody in liver transplantation has been recognized, significance of desensitization is not established yet. Our aim is to share our…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 47
- Next Page »